As expected, Mx1-CreCbfb+/56M mice died from AML with a median survival of 118.5 days, while Runx1+/R188QMx1-CreCbfb+/56M and Runx1+/R188QMx1-Cre mice were free of hematopoietic malignancy 52 weeks after pIpC treatment (Figure 5B and Supplemental Figure 8, C and D). This evidence concerns the gene RUNX1 and acute myeloid leukemia.